Parsatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer.
It acts as an immunomodulator and binds to EGFL7.
[1] This drug was developed by Genentech/Roche.
This monoclonal antibody–related article is a stub.
You can help Wikipedia by expanding it.